Anti-MET/ AUTS9/ DFNB97 monoclonal antibody

Anti-MET/ AUTS9/ DFNB97 antibody for FACS & in-vivo assay

Target products collectionGo to MET/MET products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-T40474-Ab-1/ GM-Tg-hg-T40474-Ab-2Anti-Human MET monoclonal antibodyHuman
GM-Tg-rg-T40474-Ab-1/ GM-Tg-rg-T40474-Ab-2Anti-Rat MET monoclonal antibodyRat
GM-Tg-mg-T40474-Ab-1/ GM-Tg-mg-T40474-Ab-2Anti-Mouse MET monoclonal antibodyMouse
GM-Tg-cynog-T40474-Ab-1/ GM-Tg-cynog-T40474-Ab-2Anti-Cynomolgus/ Rhesus macaque MET monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-T40474-Ab-1/ GM-Tg-felg-T40474-Ab-2Anti-Feline MET monoclonal antibodyFeline
GM-Tg-cang-T40474-Ab-1/ GM-Tg-cang-T40474-Ab-2Anti-Canine MET monoclonal antibodyCanine
GM-Tg-bovg-T40474-Ab-1/ GM-Tg-bovg-T40474-Ab-2Anti-Bovine MET monoclonal antibodyBovine
GM-Tg-equg-T40474-Ab-1/ GM-Tg-equg-T40474-Ab-2Anti-Equine MET monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-T40474-Ab-1/ GM-Tg-hg-T40474-Ab-2; GM-Tg-rg-T40474-Ab-1/ GM-Tg-rg-T40474-Ab-2;
GM-Tg-mg-T40474-Ab-1/ GM-Tg-mg-T40474-Ab-2; GM-Tg-cynog-T40474-Ab-1/ GM-Tg-cynog-T40474-Ab-2;
GM-Tg-felg-T40474-Ab-1/ GM-Tg-felg-T40474-Ab-2; GM-Tg-cang-T40474-Ab-1/ GM-Tg-cang-T40474-Ab-2;
GM-Tg-bovg-T40474-Ab-1/ GM-Tg-bovg-T40474-Ab-2; GM-Tg-equg-T40474-Ab-1/ GM-Tg-equg-T40474-Ab-2
Products NameAnti-MET monoclonal antibody
Formatmab
Target NameMET
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody, Therapeutics Target antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-MET benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    BiosimilarGMP-Bios-ab-021Pre-Made Amivantamab biosimilar, Bispecific mAb, Anti-EGFR;MET Antibody: Anti-ERBB/ERRP/HER1/mENA/ERBB1/PIG61/NISBD2;AUTS9/DFNB97/HGFR/RCCP2/c-Met therapeutic antibody
    BiosimilarGMP-Bios-ab-178Pre-Made Emibetuzumab biosimilar, Whole mAb, Anti-MET Antibody: Anti-AUTS9/DFNB97/HGFR/RCCP2/c-Met therapeutic antibody
    BiosimilarGMP-Bios-ab-656Pre-Made Bafisontamab biosimilar, Whole mAb, Anti-EGFR;MET Antibody: Anti-ERBB/ERRP/HER1/mENA/ERBB1/PIG61/NISBD2;AUTS9/DFNB97/HGFR/RCCP2/c-Met therapeutic antibody
    BiosimilarGMP-Bios-ab-401Pre-Made Onartuzumab biosimilar, Fab + di-Fc, Anti-MET Antibody: Anti-AUTS9/DFNB97/HGFR/RCCP2/c-Met therapeutic antibody
    BiosimilarGMP-Bios-ab-559Pre-Made Telisotuzumab biosimilar, Whole mAb ADC, Anti-MET Antibody: Anti-AUTS9/DFNB97/HGFR/RCCP2/c-Met therapeutic antibody
    BiosimilarGMP-Bios-INN-1017Pre-Made Telisotuzumab Vedotin Biosimilar, Whole Mab Adc, Anti-Met Antibody: Anti-AUTS9/DFNB97/HGFR/RCCP2/c-Met therapeutic antibody Drug Conjugate
    Target AntigenProducts DevelopingMulti-species MET/ AUTS9/ DFNB97 VLP (virus-like particle) (Products Developing)
    ORF Viral VectorvGMLV000394human MET Lentivirus particle
    ORF Viral VectorpGMLV000394human MET Lentivirus plasmid


    Target information

    Target IDGM-T40474
    Target NameMET
    Gene ID4233,17295,24553,704562,403438,493669,280855,100056013
    Gene Symbol and SynonymsAUTS9,c-Met,DA11,DFNB97,HGF,HGFR,MET,Par4,RCCP2
    Uniprot AccessionP08581,P97523,Q75ZY9,A0M8S8,Q769I5,Q2QLA9
    Uniprot Entry NameMET_HUMAN,MET_RAT,MET_FELCA,MET_CANLF,MET_BOVIN,MET_HORSE
    Protein Sub-locationTransmembrane Protein
    CategoryTherapeutics Target, Immuno-oncology Target, INN Index
    DiseaseNon-Small Cell Lung Cancer, Breast Cancer, gastric cancer
    Gene EnsemblENSG00000105976
    Target ClassificationCheckpoint-Immuno Oncology, Kinase

    The target: MET, gene name: MET, also named as AUTS9, DFNB97, HGFR, RCCP2, c-Met. This gene encodes a member of the receptor tyrosine kinase family of proteins and the product of the proto-oncogene MET. The encoded preproprotein is proteolytically processed to generate alpha and beta subunits that are linked via disulfide bonds to form the mature receptor. Further processing of the beta subunit results in the formation of the M10 peptide, which has been shown to reduce lung fibrosis. Binding of its ligand, hepatocyte growth factor, induces dimerization and activation of the receptor, which plays a role in cellular survival, embryogenesis, and cellular migration and invasion. Mutations in this gene are associated with papillary renal cell carcinoma, hepatocellular carcinoma, and various head and neck cancers. Amplification and overexpression of this gene are also associated with multiple human cancers. [provided by RefSeq, May 2016].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.